Condition
Posterior Blepharitis
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
80%
4 of 5 completed with results
Key Signals
4 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (2)
P 4 (1)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04469998Phase 2CompletedPrimary
Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
NCT02952079Not ApplicableCompleted
Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis
NCT00681109Phase 1CompletedPrimary
Topical IL-1-Ra for Treatment of Posterior Blepharitis
NCT01456780Phase 4Completed
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
NCT01783860Phase 2CompletedPrimary
Oral Azithromycin Versus Doxycycline in Posterior Blepharitis
Showing all 5 trials